FBLG

FibroBiologics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.97

Price (1 Year)

$8.7 $0.7

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0.1 / %30
Non-compliant assets / Total market cap %0.4 / %30
Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.

Website

Analysis (Turkish): FBLG Hissesi Caiz mi, Helal mi? FibroBiologics, Inc. Katılım Analizi